<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189160</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 032 CT</org_study_id>
    <nct_id>NCT03189160</nct_id>
  </id_info>
  <brief_title>A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome</brief_title>
  <official_title>A Phase 2 Study of Pegylated Recombinant Human Growth Hormone Injection to Treat Children of Turner Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Province Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the optimal dose of pegylated recombinant human growth hormone
      (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its
      safety and efficacy and provide scientific and reliable evidence for the medication dosage in
      Phase 3 clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of height standard deviation score before and after treatment (ΔHT SDS)</measure>
    <time_frame>52 weeks</time_frame>
    <description>The change of height standard deviation score of chronological age before and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height Velocity</measure>
    <time_frame>52 weeks</time_frame>
    <description>Annual growth rate at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ΔBA/ΔCA</measure>
    <time_frame>52 weeks</time_frame>
    <description>Bone maturation (changes of bone age/ chang of chronological age)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1(Insulin-like growth factor 1) SDS</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Turner Syndrome</condition>
  <arm_group>
    <arm_group_label>PEG-rhGH low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rhGH high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-treatment control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-rhGH low dose</intervention_name>
    <description>PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.</description>
    <arm_group_label>PEG-rhGH low dose</arm_group_label>
    <arm_group_label>PEG-rhGH high dose</arm_group_label>
    <other_name>Polyethylene Glycol Recombinant Human Somatropin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-rhGH high dose</intervention_name>
    <description>PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.</description>
    <arm_group_label>PEG-rhGH low dose</arm_group_label>
    <arm_group_label>PEG-rhGH high dose</arm_group_label>
    <other_name>Polyethylene Glycol Recombinant Human Somatropin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-treatment control group</intervention_name>
    <arm_group_label>PEG-rhGH low dose</arm_group_label>
    <arm_group_label>PEG-rhGH high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Bone age &lt;12 years

          -  Karyotype: 45, X; 45, X / 46, XXqi; 45, X / 46, XXr; 45, X / 46, XX; 46, XXqi; 46,
             XXpi; 45, X / 47, XXX; 46, XXp-; 45, X / 46, XXp-; 46, XXq-; 45X / 46, XXq-; 45, X /
             46, XX / 47, XXX, etc. (count 50 or more cells);

          -  Facial appearance and abnormalities: Patients with at least one of the following
             signs, which include but are not limited to facial pigmented nevus, short neck, webbed
             neck, low posterior hairline, low-set ears, micrognathia, high-voulted arch,
             shield-like chest, cubitus valgus, genu valgum, short 4th and 5th metacarpals, nail
             dysplasia, scoliosis, ptosis and strabismus, cardiovascular abnormalities (such as
             aortic stenosis, bicuspid aortic valve and hypertension), reproductive abnormalities
             (such as primary gonadal dysfunction), renal abnormalities, thyroid hypofunction,
             middle ear lesion, etc.

          -  Short stature: height below -2.5SD of the mean height of the same age and gender.

          -  Pre-pubertal (Tanner Stage I ) patients

          -  No history of growth hormone treatment

          -  The subject and his/her guardian sign the informed consent (if the subject is
             incapable to sign the informed consent, his/her legal guardian shall sign the name of
             the subject instead)

        Exclusion Criteria:

          -  Subjects with abnormal liver and kidney functions (ALT &gt; upper limit of normal value;
             Cr &gt; upper limit of normal value)

          -  Subjects positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests;

          -  Subjects with highly allergic constitution or allergy to proteins or investigational
             product or its excipient

          -  Subjects with systemic chronic disease and immune deficiency

          -  Patients diagnosed with tumor

          -  For patients whose tumor markers exceeding normal range in combination with other
             information, considering as potential high risks of tumor, they may be excluded from
             the treatment.

          -  Patients with mental disease

          -  Subjects with impaired glucose regulation (IGR) (including impaired fasting glucose
             (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes

          -  Subjects who took part in other clinical trials within 3 months

          -  Subjects who received medicines which may interfere GH secretion or GH function, or
             other hormones within 3 months (such as sex steroids, glucocorticoids, etc.)

          -  Other conditions which are unsuitable for this study in the opinion of the
             investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxiu Gong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohua Feng</last_name>
    <phone>0431-85170552</phone>
    <email>fengxiaohua@gensci-china.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhua Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuangjian Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Children's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongwei Du</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junfeng Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunxiu Gong, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feihong Luo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital of Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ye</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

